Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Kisspeptin-10 | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Kisspeptin-10 is the 10-amino acid C-terminal fragment of the kisspeptin family that signals directly to GnRH neurons through the kisspeptin receptor (KISS1R/GPR54), triggering GnRH release into the portal circulation. This stimulates LH and FSH secretion from anterior pituitary gonadotrophs. In men, intravenous kisspeptin-10 produces rapid dose-dependent LH rises (4.1 to 12.4 IU/L at 1 mcg/kg within 30 minutes), increases LH pulse frequency and amplitude, and subsequently elevates testosterone through the HPG axis.
Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.
Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.
Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →